X4制药 XFOR 深 沪
已收盘 02-06 16:00:00 美东时间
3.56
-0.100
-2.73%
华盛通- 最 高3.82
- 今 开3.70
- 成交量 83.19万股
- 最 低 3.524
- 昨 收 3.66
- 总市值 3.11亿
- 52周最高 16.29
- 市盈率 静 --
- 换手率 0.95%
- 52周最低 1.35
- 委 比 76.93%
- 总股本 8743.67万
- 历史最高 717.90
- 量 比 1.53
- 振 幅 8.09%
- 历史最低 3.524
- 每 手 1
- 风险率 3.30%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多X4 Pharmaceuticals to Participate in Guggenheim’s Emerging Outlook: Biotech Summit 2026
X4 Pharmaceuticals announced that its management team will participate in the Guggenheim Emerging Outlook: Biotech Summit on February 11-12, 2026 in New York. The team will host a fireside chat on February 12th at 12:30 p.m. ET and be available for one-on-one meetings with investors. A webcast of the chat will be available on the company's website, with a replay accessible for 30 days. X4 focuses on developing innovative therapies for rare hemato...
02-03 12:00
BRIEF-X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule
BRIEF-X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule Feb 2 (Reuters) - X4 Pharmaceuticals Inc XFOR.O : X4 PHARMACEUTICALS ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4) Source text: ID:nGNX23vWrm Further company coverage: XFOR.O (( Reuters.Briefs@thomsonre
02-03 05:03
X4 Pharmaceuticals vergibt neue Aktienoptionen an Mitarbeiter
X4 Pharmaceuticals vergibt neue Aktienoptionen an Mitarbeiter X4 Pharmaceuticals Inc. hat bekannt gegeben, dass am 30. Januar 2026 neuen Mitarbeitenden Aktienoptionen zum Kauf von insgesamt 20.000 Stammaktien zu einem Ausübungspreis von 3,70 US-Dollar je Aktie gewährt wurden. Die Optionen haben eine
02-03 05:01
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
X4 Pharmaceuticals granted 20,000 stock options to new employees on January 30, 2026, under its 2019 Inducement Plan. The options have a 10-year term, a $3.70 exercise price, and vest over four years. The company, focused on rare immune diseases, markets mavorixafor (XOLREMDI®) and conducts a Phase 3 trial for chronic neutropenia.
02-02 21:01
Dynavax Technologies, Omeros, Agios Pharmaceuticals, Nike And Other Big Stocks Moving Higher On Wednesday
U.S. stocks were higher, with the Dow Jones index gaining around 200 points on ...
2025-12-25 00:06
美股大行评级 | 高盛上调梅西百货目标价至22美元！ 摩根大通上调美国铝业公司目标价至45美元
今日重点评级关注：Stifel：维持X4 Pharmaceuticals"买入"评级，目标价从7.5美元升至10美元；花旗：维持UP Fintech Holding"买入"评级，目标价从17.4美元升至17.5美元
2025-12-08 08:34
Stifel Maintains Buy on X4 Pharmaceuticals, Raises Price Target to $10
Stifel analyst James Condulis maintains X4 Pharmaceuticals (NASDAQ:XFOR) with a Buy and raises the price target from $7.5 to $10.
2025-12-06 01:29
美股大行评级 | 花旗上调英伟达目标价从210美元升至220美元；DraftKings、DoubleVerify遭多家大行下调目标价
今日重点评级关注：Guggenheim：维持InflaRx"买入"评级，目标价从10美元升至22美元；巴克莱：维持Tandem糖尿病护理"超配"评级，目标价从51美元升至55美元
2025-11-11 10:49
X4 Pharmaceuticals Q3 EPS $(0.69) Beats $(0.82) Estimate, Sales $1.765M Miss $1.901M Estimate
X4 Pharmaceuticals (NASDAQ:XFOR) reported quarterly losses of $(0.69) per share which beat the analyst consensus estimate of $(0.82) by 15.85 percent. This is a 87.41 percent increase over losses of $(5.48) per share
2025-11-05 21:22
X4 Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Corporate Update
X4 Pharmaceuticals announced Q3 2025 financial results, focusing on advancing the 4WARD Phase 3 chronic neutropenia trial. The company achieved $240.3M in financings, reducing workforce by 50% to save $13M annually. Cash runway extends to end of 2028, enabling completion of the 4WARD trial and potential launch of mavorixafor in this indication.
2025-11-05 12:00
